From Virtual Molecules to Clinical Trials: How AI Is Reshaping Preclinical Drug Discovery - Summary - MDSpire

From Virtual Molecules to Clinical Trials: How AI Is Reshaping Preclinical Drug Discovery

  • By

  • Benedette Cuffari

  • May 29, 2026

  • 0 min

Share

Objective:

To explore how artificial intelligence (AI) is transforming preclinical drug discovery and development processes, particularly in efficiency.

Key Findings:
  • AI technologies are enabling faster and more efficient identification and optimization of drug candidates.
  • Despite advancements, drug development remains expensive and time-consuming, often taking 10 to 15 years.
  • About 90% of drug candidates fail during clinical trials, primarily due to lack of efficacy and toxicity issues.
Interpretation:

Limitations:
  • The high failure rate of drug candidates in clinical trials continues to pose significant challenges.
  • Eroom’s Law highlights that drug development costs are increasing despite technological advancements.
Conclusion:

Original Source(s)

From Virtual Molecules to Clinical Trials: How AI Is Reshaping Preclinical Drug Discovery

  • by Benedette Cuffari

  • May 29, 2026

Related Content

Wastewater Study Tracks Illicit Drug Use Across England

A year-long LC-MS/MS study suggests wastewater surveillance can reveal shifts in drug consumption linked to public events, weekends, and law enforcement activity

  • May 27, 2026

  • 3 min
Patient Experiences With Online Laboratory Test Presentations From Access to Activation: Systematic Review

Development and Validation of a Family Caregiver Constraint Index